Sarepta Therapeutics Faces Scrutiny over Efficacy and Safety of Gene Therapy

Strategic Insights -

Sarepta Therapeutics, a leading biotech company, has been rocked by a major restructuring announcement and a securities class action lawsuit alleging the company misled investors about the safety and efficacy of its flagship gene therapy, ELEVIDYS. The lawsuit, filed on behalf of investors, claims Sarepta withheld crucial information about significant risks associated with ELEVIDYS, including acute liver injury and failure, and failed to disclose its clinical trial protocols were inadequate to detect severe side effects.

Key Takeaways:

  • Sarepta Therapeutics announced a major restructuring on July 16, 2025, involving a 36% workforce reduction (500 employees) and plans to save $400 million annually, citing a need to adapt to changing market conditions and regulatory requirements.
  • The company agreed with the FDA to include a black box warning of acute liver injury and acute liver failure in the ELEVIDYS label, a move that has sparked concerns about the drug's safety and efficacy.
  • The securities class action lawsuit, filed in the Southern District of New York, alleges that Sarepta made false and misleading statements about the safety and efficacy of ELEVIDYS, causing investors to suffer losses.
  • The complaint claims that Sarepta failed to disclose significant risks associated with ELEVIDYS, including acute liver injury and failure, and that its clinical trial protocols were inadequate to detect severe side effects.
  • The lawsuit also alleges that Sarepta conditioned investors to believe that ELEVIDYS was a safe and effective treatment with a clear path to broader regulatory approval, while withholding crucial information about the drug's limitations.
  • Hagens Berman, a national shareholders rights firm, is investigating the lawsuit's legal claims and urges Sarepta investors who suffered substantial losses to contact the firm for more information.
  • Sarepta has faced new scrutiny from regulatory bodies, including the European Medicines Agency, which rejected ELEVIDYS due to effectiveness questions.
  • The EMA's rejection of ELEVIDYS has led to a significant drop in Sarepta's stock price, with investors continuing to express concerns about the drug's safety and efficacy.

Statistics:

  • 36% workforce reduction (500 employees) announced by Sarepta on July 16, 2025.
  • $400 million in annual cost savings expected as a result of the restructuring plan.
  • 2 reported deaths associated with acute liver failure in patients treated with ELEVIDYS.
  • 1 additional death reported due to acute liver failure in another non-ambulatory patient.
  • FDA's safety communication issued on June 24, 2025, confirming its investigation into the risk of acute liver failure associated with ELEVIDYS treatment.
  • 844-916-0895: the phone number for Hagens Berman's investigation hotline.
  • $2.9 billion: the total amount secured by Hagens Berman in corporate accountability cases.

Sources:

  • Globe Newswire, "Sarepta Therapeutics Announces Restructuring Plan" (July 16, 2025)
  • Hagens Berman, "Sarepta Therapeutics Securities Class Action" (n.d.)
  • Investor's Business Daily, "Sarepta's ELEVIDYS Rejected by European Medicines Agency" (July 25, 2025)
  • FDA, "Safety Communication: Risk of Acute Liver Failure Associated with ELEVIDYS Treatment" (June 24, 2025)